Severe acute respiratory syndrome-related coronavirus

Beckman Coulter, Lenco Diagnostic Laboratories deliver more than 20,000 highly accurate COVID-19 antibody tests each week to New York City; Congressman Max Rose and Brooklyn Borough President Eric Adams applaud boost in testing resources

Retrieved on: 
Monday, July 6, 2020
Viruses, Branches of biology, Glycoproteins, Medicine, Zoonoses, Coronaviridae, Animal virology, Severe acute respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome, Lenco, Antibody

Lenco was among the first clinical labs to receive a shipment of the new Beckman Coulter SARS-CoV-2 IgG antibody test .

Key Points: 
  • Lenco was among the first clinical labs to receive a shipment of the new Beckman Coulter SARS-CoV-2 IgG antibody test .
  • Congressman Max Rose (D-Brooklyn) applauded the boost in new testing resources, stating:
    "While we're making progress in our fight against the coronavirus, there's no path to re-opening our communities without quality, accurate and extensive testing.
  • "New York has been at the epicenter of a medical crisis unlike anything we have experienced in our country since the 1918 influenza epidemic.
  • For more information about Lenco Diagnostic Laboratories, and its commitment to being part of the solution for COVID-19, visit: https://www.lencolab.com/covid19-antibody/ .

European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19

Retrieved on: 
Friday, July 3, 2020
Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Medicine, Articles, Health, Antivirals, Zoonoses, Nitriles, Nucleotides, Organophosphates, Remdesivir, Severe acute respiratory syndrome-related coronavirus, Gilead Sciences, Severe acute respiratory syndrome

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
  • This conditional marketing authorization is an important step forward as we work together to address the treatment needs of patients across Europe.
  • The conditional marketing authorization for Veklury is supported by the U.S. National Institute of Allergy and Infectious Diseases global Phase 3 trial of remdesivir.
  • A conditional marketing authorization in Europe is initially valid for one year but can be extended or converted into an unconditional marketing authorization after the submission and assessment of additional confirmatory data.

Impact of COVID-19 on the Payments Sector in India - A Comparison Between Pre- & Revised COVID-19 Forecasts of Total Payment Card, Debit Card, and Credit & Charge Card Transactions - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 2, 2020
Professional services, Finance, Viruses, Coronaviridae, Zoonoses, Animal virology, Payment systems, Coronavirus, Debit card, Payment card, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome

This report focuses on the impact of the Coronavirus outbreak on both the economy and the cards and payments industry in India.

Key Points: 
  • This report focuses on the impact of the Coronavirus outbreak on both the economy and the cards and payments industry in India.
  • Based on proprietary datasets, the snapshot provides a detailed comparison between pre COVID-19 forecasts and revised forecasts of total payment card, debit card, and credit and charge card transactions by value and volume.
  • The Coronavirus (SARS-CoV-2) outbreak, dubbed COVID-19, is first and foremost a human tragedy affecting millions of people globally.
  • However, the IMF noted that India and China will be the only two countries that are likely to buck recession.

Sorrento Announces Selection of T-VIVA-19™ as Targeted Protein Vaccine Candidate for SARS-CoV-2

Retrieved on: 
Wednesday, July 1, 2020
Branches of biology, Medical specialties, Glycoproteins, Proteins, Immunology, Vaccination, Severe acute respiratory syndrome-related coronavirus, Fusion protein, Immunoglobulin G, Antibody, Vaccine, Protein A/G

T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.

Key Points: 
  • T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.
  • Novel protein to progress as priority vaccine candidate development program.
  • T-VIVA-19 is a recombinant fusion protein of the spike protein S1-domain and the Fc portion of the human IgG1 antibody (rS1-Fc).
  • Immunization with the rS1-Fc protein via intramuscular and intravenous injections induced antibodies against the SARS-CoV-2 protein in all mice within the first week of administration.

Researchers tracking COVID-19 in wastewater to join forces on framework for translating data into a public health response

Retrieved on: 
Wednesday, July 1, 2020
Sanitation, Articles, Academic disciplines, Health, Sewerage, Severe acute respiratory syndrome-related coronavirus, Wastewater, Public health

However, deploying sewage surveillance programsforSARS-CoV-2is complex in practice, requiring not only wastewater sampling and analysis, but also data interpretation and communication of results to public health officials who can act on it.

Key Points: 
  • However, deploying sewage surveillance programsforSARS-CoV-2is complex in practice, requiring not only wastewater sampling and analysis, but also data interpretation and communication of results to public health officials who can act on it.
  • A central goal of the collaboration is making data from their research usable to health authorities and policymakers.
  • McLellan isinvolved inimplementinga surveillance program that generates SARS-CoV-2 data for the state of Wisconsin, including weekly data at 42 wastewater treatment plants in the most populated counties.
  • The pandemic response is constantly evolving, and data and knowledge for decision-making is lacking, said McLellan, the lead investigator on the grant.

Aligos Therapeutics and KU Leuven Announce Collaboration for the Development of a Therapeutic Candidate Targeting Coronavirus

Retrieved on: 
Wednesday, July 1, 2020
Viruses, Leuven, Animal virology, Coronaviridae, Zoonoses, Coronavirus, Rega Institute for Medical Research, Severe acute respiratory syndrome-related coronavirus, Antiviral drug, KU Leuven, Severe acute respiratory syndrome

In this collaboration, Johan Neyts research group and CD3 will join forces with Aligos, whose team has extensive experience in antiviral drug discovery, development and viral protease inhibitor chemistry.

Key Points: 
  • In this collaboration, Johan Neyts research group and CD3 will join forces with Aligos, whose team has extensive experience in antiviral drug discovery, development and viral protease inhibitor chemistry.
  • Their combined objective is to develop a therapeutic candidate designed to target the SARS-CoV-2 infection as well as other coronavirus infections.
  • CD3 was set up in 2006 by KU Leuven Research & Development and the European Investment Fund (EIF) and launched a 60 million euro fund in 2016.
  • The Rega Institute for Medical Research is a biomedical research institute of KU Leuven that comprises the Laboratory of Virology and Chemotherapy, which specializes particularly in antiviral research.

UNION Receives Approval From Danish Medicines Agency to Initiate Clinical Study With Niclosamide for Treatment of COVID-19

Retrieved on: 
Wednesday, July 1, 2020
Health, Drug discovery, Chloroarenes, Niclosamide, Nitrobenzenes, RTT, Salicylanilides, Clinical trial, Severe acute respiratory syndrome-related coronavirus

Over a number of years, UNION has built a deep understanding of niclosamide and its mechanism of action.

Key Points: 
  • Over a number of years, UNION has built a deep understanding of niclosamide and its mechanism of action.
  • The extensive experience and data generated to date by UNION with niclosamide, and in particular optimized salt forms thereof, have enabled rapid progress leading to the successful approval of the Clinical Trial Application".
  • CEO and Co-founder of UNION, Dr. Rasmus Toft-Kehler concludes: "UNION has been through an amazing period of process leading to approval of the Clinical Trial Application.
  • Niclosamide has the potential to become a truly differentiated treatment of COVID-19, effectively blocking replication of SARS-CoV-2 by targeting host cells to disrupt the viral life cycle.

Huntkey Sub-brand OUCICA Won the Outstanding Contribution Award in the Emergency Project of Guangdong Province for the Prevention and Control of New Coronavirus Infection

Retrieved on: 
Tuesday, June 30, 2020
Viruses, Coronaviridae, Animal virology, Zoonoses, Coronavirus, Middle East respiratory syndrome-related coronavirus, Viral disease, Severe acute respiratory syndrome-related coronavirus

In order to fully promote the prevention and control deployment of the epidemic, the Guangdong Provincial Department of Science and Technology leads the "Guangdong Province Special Project on Emergency Response to New Coronavirus Infection Technologies."

Key Points: 
  • In order to fully promote the prevention and control deployment of the epidemic, the Guangdong Provincial Department of Science and Technology leads the "Guangdong Province Special Project on Emergency Response to New Coronavirus Infection Technologies."
  • Huntkey's sub-brand OUCICA was invited to join the topic of "Hospital Infection Prevention and Control Technology Research of New Coronavirus 2.19-nCoV Virus".
  • OUCICA, as a purifier that mainly eliminates bacteria and viruses, is very different from common air purifiers.
  • The most important thing is that it can also destroy the bacterial cell membrane and the protein of the solidified virus.

Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV

Retrieved on: 
Tuesday, June 30, 2020
FDA, Health, Infectious diseases, Other Health, Pharmaceutical, Biotechnology, Vaccination, Virology, Severe acute respiratory syndrome-related coronavirus, Attenuated vaccine, Vaccine, Branches of biology, Biology, Organisms

These initial clinical data support the further development of MV-012-968 for RSV and the application of Meissas technology to a COVID-19 vaccine candidate.

Key Points: 
  • These initial clinical data support the further development of MV-012-968 for RSV and the application of Meissas technology to a COVID-19 vaccine candidate.
  • Meissas COVID-19 vaccine candidate, MV-014-210, was developed on the companys codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines.
  • Meissas COVID-19 vaccine candidate, MV-014-210, was derived by modifying the companys RSV LAV candidate, MV-012-968, replacing the RSV glycoproteins with a functioning SARS-CoV-2 Spike protein.
  • Furthermore, building our COVID-19 vaccine candidate on our RSV vaccine platform provides safety advantages compared to a live attenuated coronavirus approach.

GRDG Sciences and Chemia Corp. Announce 3F Biofragrance Success Against COVID-19

Retrieved on: 
Tuesday, June 30, 2020
Articles, Zoonoses, Health, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Pandemic

WINTER HAVEN, Fla., June 30, 2020 /PRNewswire/ --GRDG Sciences, LLC ("GRDG") announced today that their 3F Biofragrance, developed in strategic partnership with Chemia Corporation ("Chemia"), was successful at killing SARS-CoV-2, the virus causing the COVID-19 pandemic.

Key Points: 
  • WINTER HAVEN, Fla., June 30, 2020 /PRNewswire/ --GRDG Sciences, LLC ("GRDG") announced today that their 3F Biofragrance, developed in strategic partnership with Chemia Corporation ("Chemia"), was successful at killing SARS-CoV-2, the virus causing the COVID-19 pandemic.
  • 3F Biofragrance was designed to satisfy the goals and principles of Project Bioshield and the Open Air Defense Initiative.
  • Isolates in 3F Biofragrance were able to kill the SARS-CoV-2 virus in 15 seconds at concentrations as low as 1/5000.
  • Thomas A. Meyer, Vice-President of Innovation and Sustainability for Chemia said, "We are proud to work with GRDG to develop the 3F Biofragrance technology.